You are here

  • Home
  • Archive
  • Volume 28, Issue 8
  • Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: A Single Institutional Experience of 56 Patients

Article Text

Article menu
Download PDFPDF
Uterine Cancer
Treatment Results and Prognostic Factors of Brain Metastases From Ovarian Cancer: A Single Institutional Experience of 56 Patients
  1. Ji-Woong Kwon, MD*,
  2. Joon Ho Yoon, MD†,
  3. Myong Cheol Lim, MD, PhD‡,
  4. Jungnam Joo, PhD§,
  5. Heon Yoo, MD, PhD*,
  6. Sang-Hoon Shin, MD*,
  7. Sang Yoon Park, MD, PhD‡,
  8. Sang Hyeon Lee, MD, PhD∥,
  9. Yeon-Joo Kim, MD,
  10. Joo-Young Kim, MD, PhD and
  11. Ho-Shin Gwak, MD, PhD#
  1. *Neuro-oncology Clinic, National Cancer Center, Goyang;
  2. †Department of Neurosurgery, Seoul National University College of Medicine, Seoul;
  3. ‡Center for Uterine Cancer,
  4. §Biometrics Research Branch, Research Institute,
  5. ∥Department of Radiology,
  6. Department of Radiation Oncology, and
  7. #Department of Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, Republic of Korea.
  1. Address correspondence and reprint requests to Ho-Shin Gwak, MD, PhD, Department of System Cancer Science, Graduate School of Cancer Science and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea. E-mail: nsghs{at}ncc.re.kr; halodoc{at}naver.com.

Abstract

Objectives The most appropriate treatments for brain metastases from ovarian cancer have not been established mainly because of its rarity. The objective of this study was to describe clinical results of treatment and prognostic factors of patients with brain metastases from ovarian cancer treated at a single institution.

Materials and Methods We retrieved information from the electronic medical records of 56 consecutive patients (2.8%) with brain metastases, from a total of 2008 patients with ovarian cancer. Endpoints were the pattern of treatment failure, progression-free survival, and overall survival (OS).

Results Radiation was the most common initial treatment for brain metastases (59%), followed by surgery (23%). The median progression-free survival was 9.8 months. Radiological progression was confirmed in 20 patients: 7 had leptomeningeal carcinomatosis (37%), 8 had local recurrence, and 5 had distant recurrence. Median OS was 11.25 months, and the 1-year OS rate was 48.2%. Patients received surgery for single metastasis as initial treatment showed median OS of 24.1 months, which was significantly prolonged compared with the other patients (P = 0.0002). Of the 48 patients who died, 29 (60%) died of systemic disease and 7 (15%) died of central nervous system progression. Karnofsky Performance Status greater than or equal to 70, control of systemic cancer, serous histology, and surgery for brain metastases were associated with improved OS in multivariable analysis (P < 0.05).

Conclusions Surgical resection for single or symptomatic brain metastases from ovarian cancer prolonged OS significantly. Multimodality treatment, including control of systemic cancer, appeared to be an important factor in prolonging OS.

  • Brain metastases
  • Ovarian cancer
  • Prognosis
  • Radiation
  • Surgery survival

https://doi.org/10.1097/IGC.0000000000001341

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • This work was supported by a grant from the National Cancer Center, Korea (NCC-1710871-2), and the Ministry of Health and Welfare, Research Fund (H17C1018).

    • The authors declare no conflict of interest.

    • Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal’s Web site (www.ijgc.net).